Player FM ऐप के साथ ऑफ़लाइन जाएं!
Episode 12. ASH 2022 Myeloma Recap
Manage episode 350928267 series 3369804
1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma
https://ash.confex.com/ash/2022/webprogram/Paper159606.html
https://ash.confex.com/ash/2022/webprogram/Paper168930.html
2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.
https://ash.confex.com/ash/2022/webprogram/Paper170166.html
Link to the model: https://istopmm.com/riskmodel/
3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma
https://ash.confex.com/ash/2022/webprogram/Paper159357.html
4. Talquetamab: Phase 1/2 results from Monumental-1
https://tinyurl.com/kwn9en9m
https://www.nejm.org/doi/full/10.1056/NEJMoa2204591
5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosis
https://tinyurl.com/yrvjjruv
6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myeloma
https://tinyurl.com/bde84xuw
7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
https://ash.confex.com/ash/2022/webprogram/Paper159711.html
8. Three excellent abstracts from IstopMM:
Is MGUS associated with autoimmune disease?
https://tinyurl.com/5dafcz2w
Is isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?
https://tinyurl.com/4tut3rea
Is MGUS associated with CKD?
https://tinyurl.com/34swvkj9
9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trials
https://tinyurl.com/2n78yzfh
10. Surrogacy between PFS and OS in Multiple Myeloma
https://ash.confex.com/ash/2022/webprogram/Paper163855.html
https://pubmed.ncbi.nlm.nih.gov/36495317/
52 एपिसोडस
Manage episode 350928267 series 3369804
1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma
https://ash.confex.com/ash/2022/webprogram/Paper159606.html
https://ash.confex.com/ash/2022/webprogram/Paper168930.html
2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.
https://ash.confex.com/ash/2022/webprogram/Paper170166.html
Link to the model: https://istopmm.com/riskmodel/
3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma
https://ash.confex.com/ash/2022/webprogram/Paper159357.html
4. Talquetamab: Phase 1/2 results from Monumental-1
https://tinyurl.com/kwn9en9m
https://www.nejm.org/doi/full/10.1056/NEJMoa2204591
5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosis
https://tinyurl.com/yrvjjruv
6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myeloma
https://tinyurl.com/bde84xuw
7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
https://ash.confex.com/ash/2022/webprogram/Paper159711.html
8. Three excellent abstracts from IstopMM:
Is MGUS associated with autoimmune disease?
https://tinyurl.com/5dafcz2w
Is isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?
https://tinyurl.com/4tut3rea
Is MGUS associated with CKD?
https://tinyurl.com/34swvkj9
9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trials
https://tinyurl.com/2n78yzfh
10. Surrogacy between PFS and OS in Multiple Myeloma
https://ash.confex.com/ash/2022/webprogram/Paper163855.html
https://pubmed.ncbi.nlm.nih.gov/36495317/
52 एपिसोडस
सभी एपिसोड
×प्लेयर एफएम में आपका स्वागत है!
प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।